The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...

CareMed, an independent specialty pharmacy, is in the Limited Distribution Network for Vanrafia™ (atrasentan), for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy ...

To prevent muscle loss, more physicians are emphasizing the importance of fat loss vs weight loss for patients taking GLP-1 ...

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...

To demonstrate the power of their model, the researchers applied it to two biologically significant systems: the RAS-RAF complex and G Protein-Coupled Receptors (GPCRs). The RAS-RAF complex plays ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia (atrasentan), a potent ...

generally a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5g/g. The accelerated approval of atrasentan was based on the randomized, double-blind, placebo-controlled ALIGN ...